RDGL Stock Overview
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Vivos Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.071 |
52 Week High | US$0.12 |
52 Week Low | US$0.041 |
Beta | 1.49 |
1 Month Change | 33.01% |
3 Month Change | -4.82% |
1 Year Change | 12.70% |
3 Year Change | -30.22% |
5 Year Change | 170.91% |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
RDGL | US Medical Equipment | US Market | |
---|---|---|---|
7D | 1.6% | 2.2% | 0.4% |
1Y | 12.7% | 13.3% | 28.8% |
Return vs Industry: RDGL matched the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: RDGL underperformed the US Market which returned 29.5% over the past year.
Price Volatility
RDGL volatility | |
---|---|
RDGL Average Weekly Movement | 11.3% |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDGL's share price has been volatile over the past 3 months.
Volatility Over Time: RDGL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 1 | Mike Korenko | https://www.radiogel.com |
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017.
Vivos Inc. Fundamentals Summary
RDGL fundamental statistics | |
---|---|
Market cap | US$27.68m |
Earnings (TTM) | -US$2.89m |
Revenue (TTM) | US$19.50k |
1,420x
P/S Ratio-9.6x
P/E RatioIs RDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RDGL income statement (TTM) | |
---|---|
Revenue | US$19.50k |
Cost of Revenue | US$25.54k |
Gross Profit | -US$6.04k |
Other Expenses | US$2.89m |
Earnings | -US$2.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0074 |
Gross Margin | -30.95% |
Net Profit Margin | -14,844.89% |
Debt/Equity Ratio | 0% |
How did RDGL perform over the long term?
See historical performance and comparison